MEDBOT-B(02252): Tumai's global commercial installation breakthrough exceeds one hundred units.

MEDBOT-B (02252) issued an announcement that, in terms of comprehensive orders, after preliminary internal statistics by the Group, the total comprehensive order volume of the Group's core products in the endoscopy, orthopedics, and vascular intervention fields has exceeded 230 units. Among them, the core product of TeoMai endoscopic surgery by Siasun Robot & Automation (TeoMai) has accumulated over 160 commercial orders worldwide, including nearly 120 new orders this year. According to public statistics, TeoMai's global order volume has already ranked among the top two globally by 2025. In terms of commercial installations, as of the date of this announcement, among the aforementioned comprehensive orders, the Group's various products have completed over 150 commercial installations. Among them, TeoMai's global commercial installation volume has exceeded one hundred units, and all these one hundred installations have obtained installation acceptance reports signed by users. These transaction arrangements comply with the company's revenue recognition policy and have completed revenue recognition. The company's revenue recognition policy follows Hong Kong accounting standards and industry practices. TeoMai has become the first domestic endoscopic surgery by Siasun Robot & Automation to achieve over one hundred commercial installations, proving not only its industry infrastructure-level system reliability and clinical stability but also signaling its comprehensive improvement in key systems such as quality compliance, production process, engineering verification, system delivery, clinical adaptation, and full-process guarantee capability. In the domestic market, TeoMai has made breakthrough progress in leading public hospitals and high-end non-public hospitals, with top 100 hospitals accounting for 23% of the installed hospitals, and top class A hospitals accounting for over 90%. TeoMai has gradually established a high-quality commercial installation pattern driven by clinical value and professional capabilities. With the remote technical capabilities independently developed by the Group, various levels of hospitals have achieved remote teaching, remote technical support, cross-center collaborative surgery, and other collaboration modes, making Siasun Robot & Automation surgery gradually transform into an advanced medical means that can be widely promoted, standardized training, and sustainably diffused, thus promoting the continuous spread of high-level surgical capabilities from top hospitals to regional centers and even grassroots hospitals. TeoMai's global market share continues to rise, and TeoMai is building a replicable, expandable, and sustainable growth curve in the global market. Based on the Group's deep layout of a multi-level global healthcare system and leading remote technical capabilities globally, a three-dimensional ecosystem of Siasun Robot & Automation surgery led by top global experts, deep collaboration among regional medical centers, active participation of grassroots hospitals, integration of academic systems, technical systems, and clinical systems is rapidly forming. As of now, TeoMai's overseas market layout has extensively covered over 40 countries and regions in Asia, Europe, Africa, Oceania, and South America, gaining recognition from local top institutions and achieving "multi-unit sales, multi-hospital installations" in 15 countries, achieving normalization, networking, and large-scale use in mature healthcare systems in different regions globally.